Consistent with this point, we observed that LIFR‐K620 acetylation‐mediated activation of AKT signalling depends mainly on PTEN deletion, suggesting that inhibiting LIFR‐K620 acetylation is a potential strategy to treat advanced PCa with PTEN loss. The gene discussed is AKT1; the disease is posterior cortical atrophy.